News
-
-
PRESS RELEASE
AB Science - New peer-reviewed data provide strong evidence supporting masitinib potential for the treatment of Alzheimer’s disease
New peer-reviewed data supports masitinib's potential for treating Alzheimer's disease through cognitive enhancement and neuroprotection. Phase 3 study authorized by FDA and key EU countries -
-
-
-
-
-
-
-
PRESS RELEASE
AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041, adding one more indication with long term intellectual property protection
AB Science receives Chinese patent protecting masitinib in the treatment of COVID-19 until 2041, providing long-term intellectual property protection. Collaboration with University of Chicago for COVID-19 research
